Tauriga Sciences Inc. Officially Approved to Operate as a U.S. Government Vendor
Continue reading here:
Tauriga Sciences Inc. Officially Approved to Operate as a U.S. Government Vendor
Category Archives: Global News Feed
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage
Patient screening begins immediately at NYU Langone Health
Read more here:
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage
Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat
WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that initial Phase 1 data on MB-105, a PSCA-targeted CAR T administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC), will be presented at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat, which is being held October 20 – 23, 2020.
Go here to read the rest:
Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat
GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth
Read this article:
GenMark Diagnostics Provides Preliminary Financial Results for Third Quarter 2020
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive topline data from an interim analysis of its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis (GPP), also known as the GALLOP trial. GPP is a chronic, life-threatening, rare inflammatory disease with no approved therapies.
See the original post:
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
- Application Submitted for the Treatment of Partial-Onset Seizures and Migraine
See the article here:
Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)
Indus Holdings, Inc. Pre-Announces Record Q3 2020 Revenues in Excess of $14 Million, ~15% EBITDA Margins, and Positive Operating Income
SALINAS, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Indus Holdings, Inc. ("Indus” or the “Company”) (CSE:INDS; OTCQX: INDXF), a leading, vertically-integrated, California-focused cannabis company, announced preliminary unaudited revenue and adjusted EBITDA for the third quarter ended September 30, 2020. All figures stated are in US Dollars. Based on a preliminary review, the Company currently anticipates:
The rest is here:
Indus Holdings, Inc. Pre-Announces Record Q3 2020 Revenues in Excess of $14 Million, ~15% EBITDA Margins, and Positive Operating Income
PCI Biotech: Employee share option scheme
Oslo, 06 October 2020
Here is the original post:
PCI Biotech: Employee share option scheme
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies
Article Features Oral Mucosal Immunotherapy (OMIT™) for Peanut Allergy Article Features Oral Mucosal Immunotherapy (OMIT™) for Peanut Allergy
Go here to see the original:
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies